Stay updated with breaking news from Estimated Effectiveness. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The study in JAMA Network Open evaluates the effectiveness of simultaneously administering the Pfizer-BioNTech BNT162b2 BA.4/5 COVID-19 vaccine and seasonal influenza vaccines versus separate administration. Results suggest similar or slightly increased COVID-19 outcomes and lower influenza-related outcomes with coadministration, particularly in those aged 65 and above.
Recent study assesses NVX-CoV2373 vaccine's effectiveness against Omicron variant. Findings show decreased efficacy over four months, but stable protection against symptomatic COVID-19.
The NVX-CoV2373 COVID-19 vaccine offers significant protection against symptomatic infections, but its effectiveness against SARS-CoV-2 declines within four months, according to a study in JAMA Network Open using Italian data. However, its protection against symptomatic COVID-19 seems to remain stable during this period.
A recent study published in Morbidity and Mortality Weekly Report estimated the efficacy of the JYNNEOS vaccine against mpox.
A study published in JAMA Network Open explores the protective efficacy of previous exposure to omicron subvariants and booster vaccination against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) omicron BA.5 infection.